Louis J. Vollmer

Chief Executive Officer at Iroko Pharmaceuticals LLC

Louis J. Vollmer

Louis J. Vollmer

Chief Executive Officer at Iroko Pharmaceuticals LLC

Biography

Louis J. Vollmer is President, Chief Executive Officer & Director at Iroko Pharmaceuticals LLC and President & Chief Executive Officer at Iroko Pharmaceuticals, Inc. He previously held the position of Executive Vice President at Endo Pharmaceuticals, Inc. Mr. Vollmer received an undergraduate degree from the University of Delaware.

Overview
Career Highlights

Iroko Pharmaceuticals LLC
Iroko Pharmaceuticals, Inc.

RelSci Relationships

163

Number of Boards

3

Relationships
RelSci Relationships are individuals Louis J. Vollmer likely has professional access to. A relationship does not necessarily indicate a personal connection.

Co-Founder at Phoenix IP Ventures LLC

Relationship likelihood: Strong

Founder at Kew Capital LLP

Relationship likelihood: Strong

Former Managing Director at Credit Suisse AG (London Branch)

Relationship likelihood: Strong

Founding Partner at Druid BioVentures LLC

Relationship likelihood: Strong

Chief Financial Officer & Senior Vice President at Iroko Pharmaceuticals LLC

Relationship likelihood: Strong

Former Senior Executive Vice President & Chief Administrative Officer at Rite Aid Corp.

Relationship likelihood: Strong

General Counsel & Executive Vice President at Tmunity Therapeutics, Inc.

Relationship likelihood: Strong

Senior Vice President-Corporate Development & Alliance Management at Iroko Pharmaceuticals LLC

Relationship likelihood: Strong

Former President, US Human Health at Merck & Co., Inc.

Relationship likelihood: Strong

Executive Director Global Supply Operations at Iroko Pharmaceuticals LLC

Relationship likelihood: Strong

Paths to Louis J. Vollmer
Potential Connections via
Relationship Science
You
Louis J. Vollmer
Chief Executive Officer at Iroko Pharmaceuticals LLC
Education

The University of Delaware (UD) is a state-assisted, privately governed institution that was founded in 1743. It offers 3 associate programs, 147 bachelor’s programs, 119 master's programs, 54 doctoral programs, and 15 dual graduate programs through seven colleges and in collaboration with more than 70 research centers. UD's student body encompasses more than 17,000 undergraduates, more than 3,600 graduate students and nearly 800 students in professional and continuing studies from across the country and around the globe. The University received its charter from the State of Delaware in 1833 and was designated one of the nation’s historic Land Grant colleges in 1867. Today, UD is a Land Grant, Sea Grant and Space Grant institution. The Carnegie Foundation for the Advancement of Teaching classifies UD as a research university with very high research activity—a designation accorded less than 3 percent of U.S. colleges and universities. UD ranks among the nation’s top 100 universities in federal R&D support for science and engineering.

Career History
Chief Executive Officer
2014 - Current

Iroko Pharmaceuticals LLC develops and distributes pharmaceutical products. It provides approved US products, marketed global, medical information and product patents. The company was founded in 2007 and is headquartered in Philadelphia, PA.

President & Chief Executive Officer
2014 - Current

Iroko Pharmaceuticals, Inc. develops and distributes pharmaceutical products. Its products include Indocin and Aldomet. The company was founded in 2007 and is headquartered in Boulder, CO.

Executive Vice President
Prior

Endo Pharmaceuticals, Inc. manufactures and distributes pharmaceutical products. The company provides research and development of generic pharmaceutical products for controlling pain. Its product includes Lidoderm, Percocet, Percodan, Frova, DepoDur, and Zydone. The company is headquartered in Malvern, PA.

Boards & Committees
Non-Executive Director
Prior

iCeutica, Inc. manufactures pharmaceutical products. It offers SoluMatrix platform, a drug reformulation and delivery technology for poorly water-soluble compounds. This technology enables iCeutica to make significantly improved formulations of approved and development stage drugs, some of which have been shown in late stage clinical trials to work faster, at a lower dose or be delivered to the body by an alternative route. The company was founded by James Williams and Matthew Callahan in 2005 and is headquartered in Philadelphia, PA.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Louis J. Vollmer. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Louis J. Vollmer's profile does not indicate a business or promotional relationship of any kind between RelSci and Louis J. Vollmer.